Cathie Wood's ARK ETF adjusts stock positions, buys PRME and TWST

Cathie Wood's ARK ETFs executed notable portfolio adjustments on September 9, 2025, signaling strategic shifts towards innovative healthcare and synthetic biology while reducing exposure to certain tech holdings. Key purchases included 157,413 shares of Prime Medicine Inc. ($612k) and 47,732 shares of Twist Bioscience Corp. ($1.25M), alongside increased positions in Bitmine Immersion Technologies. Concurrently, ARK divested 25,936 shares of Tempus AI Inc. ($2.08M) and continued offloading Robinhood Markets Inc. and Teradyne Inc., reflecting a reallocation of capital within its disruptive innovation mandate.

Analysis

On September 9, 2025, Cathie Wood's ARK ETFs executed a significant portfolio rebalancing, signaling a strategic capital rotation towards biotechnology and synthetic biology while reducing exposure to specific technology and fintech names. Notably, ARK's funds acquired $1.25 million of Twist Bioscience Corp (TWST) and over $612,000 of Prime Medicine Inc (PRME), indicating strong conviction in these healthcare innovators. This buying activity is further supported by a trend of accumulating Bitmine Immersion Technologies (BMNR) over the past week. Concurrently, ARK divested $2.08 million worth of Tempus AI Inc (TEM) and continued its consistent offloading of Robinhood Markets Inc (HOOD) and Teradyne Inc (TER). The scale of the sell-off in Tempus AI, juxtaposed with the significant new capital deployed into TWST and PRME, suggests a deliberate reallocation based on a revised assessment of growth prospects within ARK's disruptive innovation mandate.

Key Decisions for Investors

• Investors should note ARK's increased conviction in the biotechnology and synthetic biology sectors, evidenced by substantial new positions in Twist Bioscience (TWST) and Prime Medicine (PRME), which could signal perceived positive catalysts or undervaluation.
• The consistent and significant selling of Tempus AI (TEM), Robinhood (HOOD), and Teradyne (TER) warrants caution, and holders of these stocks may want to re-evaluate their investment thesis as this divestment by a key innovation fund could indicate a deteriorating outlook.
• Monitor ARK's trading activity for continuation of this trend, as a sustained capital flow from specific tech stocks into the biotech sector would reinforce the thesis of a major strategic pivot.
• Consider the net capital flow; the divestment of $2.08 million from a single name (TEM) against similarly sized new investments suggests this is a high-conviction reallocation rather than simple portfolio trimming.